MeiraGTx (NASDAQ:MGTX – Get Free Report) and Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) are both healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, profitability, institutional ownership, dividends, valuation and risk.
Insider & Institutional Ownership
67.5% of MeiraGTx shares are owned by institutional investors. 7.4% of MeiraGTx shares are owned by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Analyst Ratings
This is a breakdown of recent ratings for MeiraGTx and Ascendis Pharma A/S, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| MeiraGTx | 1 | 0 | 5 | 2 | 3.00 |
| Ascendis Pharma A/S | 0 | 1 | 17 | 2 | 3.05 |
Profitability
This table compares MeiraGTx and Ascendis Pharma A/S’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| MeiraGTx | 19.87% | 283.85% | 29.39% |
| Ascendis Pharma A/S | 70.99% | 32.54% | 7.71% |
Volatility & Risk
MeiraGTx has a beta of 1.27, indicating that its stock price is 27% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.
Valuation & Earnings
This table compares MeiraGTx and Ascendis Pharma A/S”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| MeiraGTx | $81.39 million | 16.39 | -$114.20 million | $0.71 | 19.56 |
| Ascendis Pharma A/S | $814.57 million | 20.72 | -$258.00 million | $12.89 | 20.99 |
MeiraGTx has higher earnings, but lower revenue than Ascendis Pharma A/S. MeiraGTx is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Summary
Ascendis Pharma A/S beats MeiraGTx on 8 of the 14 factors compared between the two stocks.
About MeiraGTx
MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.
About Ascendis Pharma A/S
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
Receive News & Ratings for MeiraGTx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MeiraGTx and related companies with MarketBeat.com's FREE daily email newsletter.
